Study TO Prevent Diabetes With Short-term Insulin Glargine Only (STOP-GO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01276912
Recruitment Status : Unknown
Verified January 2011 by Beijing Tongren Hospital.
Recruitment status was:  Recruiting
First Posted : January 14, 2011
Last Update Posted : January 14, 2011
Information provided by:
Beijing Tongren Hospital

Brief Summary:
  • Pre-diabetes is a significant risk factor for the development of type 2 diabetes, as well as macrovascular and microvascular complication.
  • Previous studies show that 50% or more loss in islet B-cell function even in Pre-diabetes phase. The early insulin therapy in pre-diabetes may be a strategy in preventing metabolic disorders and cardiovascular disease.
  • The objective of this study is to find if an initial insulin glargine intervention in pre-diabetes (IGT and /or IFG) could be a strategy in preventing type 2 Diabetes.
  • Pre-diabetes subjects will receive a insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal. Insulin glargine treatment will be maintained for three months thereafter to find if it can prevent diabetes.

Condition or disease Intervention/treatment Phase
Pre-diabetes Drug: Insulin glargine Behavioral: Lifestyle counseling Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2420 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multicenter, Randomized, Controlled Trial to Prevent Diabetes With Short-term Insulin Glargine Treatment or Lifestyle Intervention
Study Start Date : January 2011
Estimated Primary Completion Date : October 2013
Estimated Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prediabetes
U.S. FDA Resources

Intervention Details:
    Drug: Insulin glargine
    Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
    Behavioral: Lifestyle counseling
    To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.

Primary Outcome Measures :
  1. HbA1c >= 6.5% [ Time Frame: Two years ]

Secondary Outcome Measures :
  1. FPG >= 7.0 for two times in a month. [ Time Frame: Two years ]
  2. HbA1c >= 7.0% [ Time Frame: Two years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   25 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. All participants are voluntary and write informed consent 2 weeks before enrollment.
  2. Fasting Blood Glucose between >= 5.6mmol/L and <7.0mmol/L, and HbA1c between >= 5.7% and <6.5%.
  3. Both male and female aged between >= 25 and ≤ 65 years.
  4. Participants have the ability to use self-monitoring devices to measure their blood glucose level and practice self-insulin injection.
  5. Have the ability and willingness to complete the study logs and questionnaires.
  6. Pregnancy test of all child-bearing age women should be negative, and they agree to adopt contraceptive measures in the study process.

Exclusion Criteria:

  1. With previous diagnosis of diabetes or application of hypoglycemic drugs.
  2. Preliminary screen for fasting plasma glucose lever ≥7.0mmol/L or <5.6mmol/L.
  3. Preliminary screen for HbA1c result HbA1c<5.7% or ≥ 6.5%.
  4. Receiving cancer treatment in the past 5 years.
  5. Preliminary diagnostic anti-HIV test result positive, with no serological testing.
  6. People with active tuberculosis.
  7. Persons hospitalized for heart disease and received the treatment measures (such as coronary artery bypass graft CABG, percutaneous transluminal coronary angioplasty PTCA), while not include diagnostic measures (such as percutaneous coronary angiography) in the past 6 months.
  8. Cardiac function evaluated by New York Heart Association criteria (NYHA) ≥ 3 cardiac function level
  9. Uncontrolled high blood pressure - systolic blood pressure > 180mmHg or diastolic blood pressure > 105mmHg after treatment.
  10. Stroke or transient ischemic attack episode in the past 6 months.
  11. With chronic hepatitis or active liver disease, or serum AST or ALT 2.5 times the upper limit of normal.
  12. Male serum creatinine ≥ 124μmol/L (1.4mg/dL); Female serum creatinine ≥ 115μmol/L (1.3mg/dL).
  13. Systemic glucocorticoids applications, but other than local, eye, and inhalation applications.
  14. Anemia: male hematocrit <36.0%; female <33.0%.
  15. Other chronic diseases which may lead to the expected life less than 6 years or conditions that may affect life expectancy.
  16. Mental disorder history.
  17. Alcohol consumption (average 50g or more high spirits drink or 100g or more low spirits drink) or drug abuse.
  18. Unable or unwilling to sign informed consent.
  19. Cannot communicate or contact with the clinical staff.
  20. Unwilling to receive insulin injection therapy or conduct self-monitoring of blood glucose.
  21. Unsatisfied control of thyroid disease - subjects who are suffering thyroid disease or receiving anti-thyroid drugs or thyroid hormone treatment, show the sensitive TSH abnormalities (except for patients with low TSH who have the history of thyroid tumor or thyroid cancer receiving the inhibitor treatment).
  22. Any other factors that may affect compliance or adverse events reported during the research program.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01276912

Contact: Jin-Kui Yang, M.D., Ph.D. +86-10-58268445

Beijing Tongren Hospital Recruiting
Beijing, China, 100730
Contact: Jin-Kui Yang, M.D., Ph.D.    +86-10-58268445   
Sponsors and Collaborators
Beijing Tongren Hospital

Responsible Party: Jin-Kui Yang/Professor, Department of Endocrinology, Beijing Tongren Hospital, Capital Medical University Identifier: NCT01276912     History of Changes
Other Study ID Numbers: STOP-GO-2010
First Posted: January 14, 2011    Key Record Dates
Last Update Posted: January 14, 2011
Last Verified: January 2011

Additional relevant MeSH terms:
Diabetes Mellitus
Prediabetic State
Glucose Intolerance
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin Glargine
Hypoglycemic Agents
Physiological Effects of Drugs